STE · News · 20261112N
Acquisition / Partnership / Divestiture
STERIS plc · 2026-11-12 · Importance 71 · Surprise 60 · In source text
STERIS priced $1.5 billion of senior notes to help fund its pending acquisition of Xodus Medical. The offering comprises $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. Proceeds, term-loan borrowings, and cash are intended to cover the acquisition, related expenses, and general corporate needs; closing was expected around November 24, 2026. The acquisition is described as expanding STERIS's consumables offering.
Key facts
- STERIS priced $1.5 billion in senior notes: $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. source
- STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of Xodus Medical, related expenses, and general corporate needs. source
- STERIS's senior notes offering is expected to close around November 24, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | +11.9% | STERIS priced $1.5 billion in senior notes: $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. |
| liability | negative | committed | -11.9% | STERIS priced $1.5 billion in senior notes: $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. |
| cash | negative | probable | — | STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of… |
| assets | positive | probable | — | STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of… |
| liability | negative | probable | — | STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of… |